KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Payables (2016 - 2026)

TherapeuticsMD filings provide 17 years of Payables readings, the most recent being $15000.0 for Q1 2026.

  • On a quarterly basis, Payables fell 91.48% to $15000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $15000.0, a 91.48% decrease, with the full-year FY2025 number at $377000.0, up 46.12% from a year prior.
  • Payables hit $15000.0 in Q1 2026 for TherapeuticsMD, down from $377000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $20.8 million in Q1 2022 to a low of $15000.0 in Q1 2026.
  • Median Payables over the past 5 years was $1.5 million (2023), compared with a mean of $3.7 million.
  • Biggest five-year swings in Payables: crashed 98.75% in 2023 and later surged 1011.89% in 2025.
  • TherapeuticsMD's Payables stood at $2.2 million in 2022, then crashed by 98.75% to $27000.0 in 2023, then soared by 855.56% to $258000.0 in 2024, then skyrocketed by 46.12% to $377000.0 in 2025, then plummeted by 96.02% to $15000.0 in 2026.
  • The last three reported values for Payables were $15000.0 (Q1 2026), $377000.0 (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.